Equities

Sedana Medical AB (publ)

Sedana Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)11.96
  • Today's Change-0.300 / -2.45%
  • Shares traded292.33k
  • 1 Year change-35.00%
  • Beta0.6087
Data delayed at least 15 minutes, as of Nov 22 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Company’s main shareholders are board members, Linc AB and Magiola Consulting AB.

  • Revenue in SEK (TTM)174.14m
  • Net income in SEK-57.24m
  • Incorporated2004
  • Employees78.00
  • Location
    Sedana Medical AB (publ)Vendevagen 89DANDERYD 182 32SwedenSWE
  • Phone+46 812405200
  • Fax+46 812405296
  • Websitehttps://sedanamedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gentian Diagnostics ASA146.78m2.22m631.69m58.00324.803.9255.744.300.12620.12629.3510.470.77921.698.402,533,190.001.18-10.761.33-11.8651.6941.461.51-26.995.01--0.0394--32.9827.6354.92---4.92--
Omda AS420.67m-25.98m647.42m271.00--10.2422.781.54-1.27-1.2720.923.030.584737.9313.471,447,038.00-3.83-4.92-7.72-6.3793.0790.22-6.55-9.831.150.06810.8875--12.3019.83179.30---3.93--
Senzime AB (publ)55.29m-131.46m649.41m52.00--2.41--11.74-1.09-1.090.45952.380.15331.574.91---36.44-35.69-39.12-38.0033.27-20.59-237.75-558.682.62--0.0739--154.7761.90-1.09---3.69--
ADDvise Group AB (publ)1.63bn114.40m752.08m643.0020.223.053.570.46250.59350.59358.383.930.5658.375.772,606,250.003.983.724.824.7742.0748.957.045.891.402.350.69690.940544.3038.6227.62--30.35--
OssDsign AB127.49m-90.44m776.39m25.00--3.62--6.09-1.00-1.001.352.200.40331.325.962,656,063.00-28.61-37.92-31.51-43.5688.6468.10-70.94-203.065.44-20.450.01--96.8453.26-31.30---56.16--
Optomed Oyj157.57m-69.40m901.75m113.00--3.15--5.72-0.3355-0.33550.7631.260.42671.754.06119,307.00-18.79-12.95-22.82-15.9064.8065.69-44.04-27.842.76-20.420.1313--3.003.4718.84--7.26--
C Rad AB497.02m53.43m913.09m94.0017.533.1014.591.841.581.5814.728.961.235.042.725,712,816.0013.255.0919.167.0246.3043.1210.814.862.32--0.00490.0040.9217.44375.0510.8933.69--
Bactiguard Holding AB254.96m-56.11m1.07bn163.00--3.67--4.19-1.60-1.607.289.370.37063.847.601,174,917.00-8.16-7.56-11.32-8.8147.5347.91-22.01-26.280.5898-2.720.4175---11.966.46-161.71--8.43--
BioPorto A/S54.22m-95.22m1.12bn36.00--8.26--20.62-0.163-0.1630.09390.20140.33763.396.121,126,000.00-59.29-71.10-74.24-96.5570.6263.38-175.62-239.224.91-52.720.0507--6.873.5425.81---51.56--
Paxman AB (publ)238.86m28.64m1.20bn102.0041.918.2125.525.011.501.5012.547.671.312.746.562,624,791.0015.66-5.0820.74-7.7670.2769.3811.99-5.071.9812.730.0838--43.9929.35180.69--6.26--
Sedana Medical AB (publ)174.14m-57.24m1.22bn78.00--1.28--6.99-0.5763-0.57631.759.560.16971.1610.142,204,317.00-5.58-5.77-5.84-6.0870.6064.06-32.87-36.136.02-30.480.0076--25.2321.5918.90--42.12--
Nordhealth As506.12m-95.70m1.68bn403.00--3.3257.593.32-1.23-1.236.5011.210.475--9.491,282,595.00-8.98---10.01--85.89---18.91------0.00--18.60--21.96------
Genovis AB129.73m27.91m1.78bn32.0063.808.0145.4613.730.42630.42631.983.390.4239----3,506,189.009.1218.569.8021.4564.6965.5121.5123.88----0.25550.0054.5435.56449.56--47.59--
Data as of Nov 22 2024. Currency figures normalised to Sedana Medical AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

33.60%Per cent of shares held by top holders
HolderShares% Held
E. �hman J :or Fonder ABas of 31 May 20246.93m6.98%
Swedbank Robur Fonder ABas of 30 Oct 20244.67m4.70%
Handelsbanken Fonder ABas of 31 Oct 20244.15m4.18%
Premier Fund Managers Ltd.as of 31 Jul 20243.81m3.83%
Highclere International Investors LLPas of 31 May 20243.31m3.33%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Sep 20233.05m3.07%
AMF Fonder ABas of 31 May 20242.49m2.51%
Amundi Asset Management SA (Investment Management)as of 30 Sep 20241.90m1.91%
Tredje AP-fondenas of 31 Dec 20231.74m1.75%
AXA Investment Managers (Paris) SAas of 31 Jul 20241.33m1.34%
More ▼
Data from 30 Aug 2024 - 13 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.